Last reviewed 2026-04-23 · How we verify

UC-MSCs treatment

UC-MSCs treatment involves the use of umbilical cord-derived mesenchymal stem cells to modulate the immune system and promote tissue repair.

UC-MSCs treatment involves the use of umbilical cord-derived mesenchymal stem cells to modulate the immune system and promote tissue repair. Used for Treatment of graft-versus-host disease.

At a glance

Mechanism of action

UC-MSCs treatment works by releasing anti-inflammatory cytokines and growth factors that help to reduce inflammation and promote the healing of damaged tissues. This can lead to improved outcomes in various conditions, including those related to immune system dysfunction and tissue damage.

Approved indications

• Treatment of graft-versus-host disease

Common side effects

• Bacterial infection
• Tumor progression

Key clinical trials

• Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease (PHASE2)
• Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS (PHASE2)
• Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease (PHASE1, PHASE2)
• Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells (PHASE1)
• Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis (PHASE1, PHASE2)
• Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients (PHASE2)
• Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct (PHASE1, PHASE2)
• Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.